Epidemic Alert: Unveiling the Diabetes Surge in Jammu
A recent study reveals alarming diabetes statistics in Jammu, with 18.9% prevalence overall and 26.5% in urban areas. The ICMR-INDIAB study highlights undiagnosed diabetes, prediabetes rates, and other health concerns, prompting calls for urgent action against non-communicable diseases in the region.
- Country:
- India
The prevalence of diabetes in Jammu has reached concerning levels, with an overall rate of 18.9% as unveiled by a new study. The condition is significantly higher in urban areas, affecting 26.5% of the population, compared to 14.5% in rural settings. Collaborating with the Madras Diabetes Research Foundation, the Indian Council of Medical Research (ICMR) disclosed these statistics through their ICMR-India Diabetes (ICMR-INDIAB) national study, emphasizing the growing burden of non-communicable diseases in Jammu and Kashmir.
The study further indicates that a staggering 40% of individuals living with diabetes remain undiagnosed. Beyond diabetes, other health issues such as hypertension (27.1%), generalized obesity (41.7%), and abdominal obesity (62.7%) were found to be prevalent in Jammu. These findings, shared during an event attended by Union Minister Jitendra Singh, underscore the importance of shifting focus towards proactive health management and intervention strategies.
Minister Singh highlighted the ICMR-INDIAB study as a crucial step in providing reliable data for researchers, academicians, and government bodies. He commended the efforts of Dr. V Mohan, the National Coordinator, and the Madras Diabetes Research Foundation for their work on this extensive survey. Covering all Indian states and union territories, this survey aims to furnish a comprehensive picture of diabetes and associated metabolic disorders in India, emphasizing the need for targeted prevention and control programs.
(With inputs from agencies.)
ALSO READ
Zealand Pharma's Monotherapy Approach Gains Momentum Amid Obesity Drug Market Fluctuations
Novo Nordisk Faces Setback as Obesity Drug Trial Falls Short
Novo Nordisk's CagriSema Falls Short in Obesity Drug Trial
Novo Nordisk's Setback: Obesity Drug Trial Results Raise Questions
Novo Nordisk Faces Setback as Obesity Drug Falls Short of Expectations